Randomized controlled trial of Sajabalssuk (Artemisia princeps Pampanini) to treat pre-diabetes

Yun Young Cho; Nam In Baek; Hae Gon Chung; Tae Sook Jeong; Kyung Tae Lee; Seon Min Jeon; Hye Jin Kim; Robin A. McGregor; Myung Sook Choi

doi:10.1016/j.eujim.2012.01.009

Randomized controlled trial of Sajabalssuk (Artemisia princeps Pampanini) to treat pre-diabetes

Yun Young Cho, Nam In Baek, Hae Gon Chung, Tae Sook Jeong, Kyung Tae Lee, Seon Min Jeon, Hye Jin Kim, Robin A. McGregor, Myung Sook Choi

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Introduction: Alternative complementary therapy with medicinal herbs may help restore normal fasting glycemia in pre-diabetes and therefore delay or prevent T2D. The aim of this randomized controlled trial was to assess the efficacy of Sajabalssuk (Artemisia princeps Pampanini) extract to improve fasting glycemia in pre-diabetes. Methodology: Ninety-nine subjects with pre-diabetes (100. mg/dL. <. impaired fasting glucose. <. 125. mg/dL) were randomly assigned into placebo (starch, 2000. mg/day), positive-control (pinitol, 1140. mg/day), and SBE (Sajabalssuk extract 3000. mg/day) groups for 9. weeks. Primary outcomes were fasting blood glucose and HbA1c. Secondary outcomes were insulin resistance, plasma lipid profile and body composition. Dietary intake was also analyzed, and safety was assessed with plasma liver toxicology markers. Results: Nine weeks of SBE treatment significantly lowered fasting blood glucose (-16.51. ±. 2.78%, p<. 0.05) compared placebo or positive-control, effectively restoring normal fasting glycemia. Furthermore, SBE treatment significantly reduced HbA1c (-7.81. ±. 3.39%, p<. 0.05) and insulin resistance (-14.71. ±. 20.37%, p<. 0.05) compared to placebo or positive-control treatment. In addition, SBE treatment improved non-HDL-cholesterol (-11.57. ±. 3.94%, p<. 0.05) and HDL-cholesterol (10.90. ±. 4.35%, p<. 0.05) compared to placebo and positive-control. However, SBE treatment had no effect on other secondary outcomes including atherogenic biomarkers, blood pressure and body composition. Finally, plasma liver toxicology markers were unaltered by SBE treatment. Conclusions: Pre-diabetes treatment with the medicinal herb Sajabalssuk (3000. mg/day) for 9. weeks can improve fasting blood glucose, HbA1c and reduce insulin resistance. SBE treatment appears to have a secondary benefit leading to improved plasma non-HDL and HDL-cholesterol levels. In conclusion, Sajabalssuk extract may provide a useful alternative therapy for management of pre-diabetes.

Original language	English
Pages (from-to)	e299-e308
Journal	European Journal of Integrative Medicine
Volume	4
Issue number	3
DOIs	https://doi.org/10.1016/j.eujim.2012.01.009
Publication status	Published - Sept 2012

Bibliographical note

Funding Information:
This work was supported by a grant from the Ganghwa R&D Center and by the SRC Program (2012-0000644) of the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science and Technology .

Keywords

Artemisia princeps Pampanini
Fasting blood glucose
HOMA-IR
HbA1c
Pinitol
Randomized controlled trial

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eujim.2012.01.009

Cite this

@article{00e02d50d3eb49cda4e36e2d6e4130d5,

title = "Randomized controlled trial of Sajabalssuk (Artemisia princeps Pampanini) to treat pre-diabetes",

abstract = "Introduction: Alternative complementary therapy with medicinal herbs may help restore normal fasting glycemia in pre-diabetes and therefore delay or prevent T2D. The aim of this randomized controlled trial was to assess the efficacy of Sajabalssuk (Artemisia princeps Pampanini) extract to improve fasting glycemia in pre-diabetes. Methodology: Ninety-nine subjects with pre-diabetes (100. mg/dL. <. impaired fasting glucose. <. 125. mg/dL) were randomly assigned into placebo (starch, 2000. mg/day), positive-control (pinitol, 1140. mg/day), and SBE (Sajabalssuk extract 3000. mg/day) groups for 9. weeks. Primary outcomes were fasting blood glucose and HbA1c. Secondary outcomes were insulin resistance, plasma lipid profile and body composition. Dietary intake was also analyzed, and safety was assessed with plasma liver toxicology markers. Results: Nine weeks of SBE treatment significantly lowered fasting blood glucose (-16.51. ±. 2.78%, p<. 0.05) compared placebo or positive-control, effectively restoring normal fasting glycemia. Furthermore, SBE treatment significantly reduced HbA1c (-7.81. ±. 3.39%, p<. 0.05) and insulin resistance (-14.71. ±. 20.37%, p<. 0.05) compared to placebo or positive-control treatment. In addition, SBE treatment improved non-HDL-cholesterol (-11.57. ±. 3.94%, p<. 0.05) and HDL-cholesterol (10.90. ±. 4.35%, p<. 0.05) compared to placebo and positive-control. However, SBE treatment had no effect on other secondary outcomes including atherogenic biomarkers, blood pressure and body composition. Finally, plasma liver toxicology markers were unaltered by SBE treatment. Conclusions: Pre-diabetes treatment with the medicinal herb Sajabalssuk (3000. mg/day) for 9. weeks can improve fasting blood glucose, HbA1c and reduce insulin resistance. SBE treatment appears to have a secondary benefit leading to improved plasma non-HDL and HDL-cholesterol levels. In conclusion, Sajabalssuk extract may provide a useful alternative therapy for management of pre-diabetes.",

keywords = "Artemisia princeps Pampanini, Fasting blood glucose, HOMA-IR, HbA1c, Pinitol, Randomized controlled trial",

author = "Cho, {Yun Young} and Baek, {Nam In} and Chung, {Hae Gon} and Jeong, {Tae Sook} and Lee, {Kyung Tae} and Jeon, {Seon Min} and Kim, {Hye Jin} and McGregor, {Robin A.} and Choi, {Myung Sook}",

note = "Funding Information: This work was supported by a grant from the Ganghwa R&D Center and by the SRC Program (2012-0000644) of the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science and Technology . ",

year = "2012",

month = sep,

doi = "10.1016/j.eujim.2012.01.009",

language = "English",

volume = "4",

pages = "e299--e308",

journal = "European Journal of Integrative Medicine",

issn = "1876-3820",

publisher = "Elsevier GmbH",

number = "3",

}

TY - JOUR

T1 - Randomized controlled trial of Sajabalssuk (Artemisia princeps Pampanini) to treat pre-diabetes

AU - Cho, Yun Young

AU - Baek, Nam In

AU - Chung, Hae Gon

AU - Jeong, Tae Sook

AU - Lee, Kyung Tae

AU - Jeon, Seon Min

AU - Kim, Hye Jin

AU - McGregor, Robin A.

AU - Choi, Myung Sook

N1 - Funding Information: This work was supported by a grant from the Ganghwa R&D Center and by the SRC Program (2012-0000644) of the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science and Technology .

PY - 2012/9

Y1 - 2012/9

N2 - Introduction: Alternative complementary therapy with medicinal herbs may help restore normal fasting glycemia in pre-diabetes and therefore delay or prevent T2D. The aim of this randomized controlled trial was to assess the efficacy of Sajabalssuk (Artemisia princeps Pampanini) extract to improve fasting glycemia in pre-diabetes. Methodology: Ninety-nine subjects with pre-diabetes (100. mg/dL. <. impaired fasting glucose. <. 125. mg/dL) were randomly assigned into placebo (starch, 2000. mg/day), positive-control (pinitol, 1140. mg/day), and SBE (Sajabalssuk extract 3000. mg/day) groups for 9. weeks. Primary outcomes were fasting blood glucose and HbA1c. Secondary outcomes were insulin resistance, plasma lipid profile and body composition. Dietary intake was also analyzed, and safety was assessed with plasma liver toxicology markers. Results: Nine weeks of SBE treatment significantly lowered fasting blood glucose (-16.51. ±. 2.78%, p<. 0.05) compared placebo or positive-control, effectively restoring normal fasting glycemia. Furthermore, SBE treatment significantly reduced HbA1c (-7.81. ±. 3.39%, p<. 0.05) and insulin resistance (-14.71. ±. 20.37%, p<. 0.05) compared to placebo or positive-control treatment. In addition, SBE treatment improved non-HDL-cholesterol (-11.57. ±. 3.94%, p<. 0.05) and HDL-cholesterol (10.90. ±. 4.35%, p<. 0.05) compared to placebo and positive-control. However, SBE treatment had no effect on other secondary outcomes including atherogenic biomarkers, blood pressure and body composition. Finally, plasma liver toxicology markers were unaltered by SBE treatment. Conclusions: Pre-diabetes treatment with the medicinal herb Sajabalssuk (3000. mg/day) for 9. weeks can improve fasting blood glucose, HbA1c and reduce insulin resistance. SBE treatment appears to have a secondary benefit leading to improved plasma non-HDL and HDL-cholesterol levels. In conclusion, Sajabalssuk extract may provide a useful alternative therapy for management of pre-diabetes.

AB - Introduction: Alternative complementary therapy with medicinal herbs may help restore normal fasting glycemia in pre-diabetes and therefore delay or prevent T2D. The aim of this randomized controlled trial was to assess the efficacy of Sajabalssuk (Artemisia princeps Pampanini) extract to improve fasting glycemia in pre-diabetes. Methodology: Ninety-nine subjects with pre-diabetes (100. mg/dL. <. impaired fasting glucose. <. 125. mg/dL) were randomly assigned into placebo (starch, 2000. mg/day), positive-control (pinitol, 1140. mg/day), and SBE (Sajabalssuk extract 3000. mg/day) groups for 9. weeks. Primary outcomes were fasting blood glucose and HbA1c. Secondary outcomes were insulin resistance, plasma lipid profile and body composition. Dietary intake was also analyzed, and safety was assessed with plasma liver toxicology markers. Results: Nine weeks of SBE treatment significantly lowered fasting blood glucose (-16.51. ±. 2.78%, p<. 0.05) compared placebo or positive-control, effectively restoring normal fasting glycemia. Furthermore, SBE treatment significantly reduced HbA1c (-7.81. ±. 3.39%, p<. 0.05) and insulin resistance (-14.71. ±. 20.37%, p<. 0.05) compared to placebo or positive-control treatment. In addition, SBE treatment improved non-HDL-cholesterol (-11.57. ±. 3.94%, p<. 0.05) and HDL-cholesterol (10.90. ±. 4.35%, p<. 0.05) compared to placebo and positive-control. However, SBE treatment had no effect on other secondary outcomes including atherogenic biomarkers, blood pressure and body composition. Finally, plasma liver toxicology markers were unaltered by SBE treatment. Conclusions: Pre-diabetes treatment with the medicinal herb Sajabalssuk (3000. mg/day) for 9. weeks can improve fasting blood glucose, HbA1c and reduce insulin resistance. SBE treatment appears to have a secondary benefit leading to improved plasma non-HDL and HDL-cholesterol levels. In conclusion, Sajabalssuk extract may provide a useful alternative therapy for management of pre-diabetes.

KW - Artemisia princeps Pampanini

KW - Fasting blood glucose

KW - HOMA-IR

KW - HbA1c

KW - Pinitol

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84867141331&partnerID=8YFLogxK

U2 - 10.1016/j.eujim.2012.01.009

DO - 10.1016/j.eujim.2012.01.009

M3 - Article

AN - SCOPUS:84867141331

SN - 1876-3820

VL - 4

SP - e299-e308

JO - European Journal of Integrative Medicine

JF - European Journal of Integrative Medicine

IS - 3

ER -

Randomized controlled trial of Sajabalssuk (Artemisia princeps Pampanini) to treat pre-diabetes

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this